Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRISPR 'Not Good Enough' For CAR-T Product Manufacturing

This article was originally published in Scrip

Executive Summary

CRISPR techniques are just not accurate enough for the precision gene editing required for the scalable manufacture of CAR-T therapies, according to Cellectis CEO Andre Choulika. Cellectis has an 'off the shelf' CAR-T product for the treatment of leukemia which targets the CD19 antigen, the same target other companies in the CAR-T space such as Novartis, Kite Pharma and Juno Therapeutics are focused on.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC063746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel